House Dust Mite Disease Market to Exhibit Substantial Growth at a CAGR of 3.5%
2026年 07月 27日
The House Dust Mite Disease (HDMD) market is witnessing steady growth, driven by the rising global prevalence of allergic rhinitis and asthma associated with indoor allergens. The increasing adoption of allergen-specific immunotherapies, particularly sublingual tablets, is expanding treatment options and supporting market growth. Furthermore, the anticipated launch of emerging therapies such as HAL Allergy's PURETHAL Mites, Probelte Pharma's BELTAVAC, Inmunotek's MM09, T-Balance Therapeutics' tregalizumab, and others is expected to further strengthen the market.
DelveInsight's House Dust Mite Disease Market Insights report provides a comprehensive overview of current treatment practices, emerging therapies, market share of individual treatments, and the current as well as forecasted market size from 2020 to 2034 across major markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and China.
House Dust Mite Disease Market Summary
The House Dust Mite Disease market was valued at USD 9.2 billion across the leading markets (United States, EU4, the United Kingdom, Japan, and China) in 2024.
China accounted for the largest share of the HDMD market, representing approximately 35% of the total market across the 7MM + China.
In 2024, the prevalent HDMD patient population was estimated at 40 million cases, driven by continuous indoor exposure to house dust mites, increasing atopy rates, rapid urbanization, and lifestyle changes that encourage more time spent indoors.
Leading companies, including HAL Allergy, Probelte Pharma, Inmunotek, T-Balance Therapeutics, and others, are actively developing novel therapies that are expected to enter the market in the coming years.
Promising pipeline therapies include House Dust Mite Allergy Vaccine (PURETHAL Mites), BELTAVAC, MM09, Tregalizumab, and others.
Discover the new House Dust Mite Disease treatment:
https://www.delveinsight.com/sample-request/house-dust-mite-disease-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr
Key Factors Driving the Growth of the House Dust Mite Disease Market
Rising Asthma Burden
In 2024, the diagnosed prevalent asthma population across the 7MM was approximately 113 million. This figure is expected to increase through 2034, supported by advances in diagnostic technologies, broader genetic testing, complement assays, and multidisciplinary biopsy evaluation.
Current Sublingual Immunotherapy Options
Currently, ODACTRA (ALK-Abelló) and ACTAIR (Stallergenes Greer) are the only approved therapies using a similar sublingual administration approach for patients with allergic rhinitis.
Mid- to Late-Stage HDM Therapies
Several therapies, including PURETHAL Mites, BELTAVAC, MM09, and tregalizumab, are under evaluation for HDM-induced allergic rhinitis. However, limited clinical updates, restricted efficacy and safety data, and the lack of advanced-stage trial results continue to create uncertainty regarding their regulatory prospects.
Tregalizumab: A Differentiated Treg-Targeted Therapy
Developed by T-Balance Therapeutics, tregalizumab selectively activates regulatory T cells (Tregs) and demonstrates a well-characterized pharmacokinetic profile, highlighting its potential as an innovative treatment option.
House Dust Mite Disease Market Analysis
The management of HDMD primarily focuses on symptom relief through off-label and supportive therapies due to the absence of approved disease-modifying treatments.
Common treatment approaches include:
Antihistamines
Intranasal corticosteroids
Leukotriene receptor antagonists
Allergen immunotherapy (AIT)
Although AIT remains a key treatment option, its effectiveness varies among patients. Long treatment durations, poor adherence, and safety concerns, including the possibility of systemic allergic reactions, often limit its real-world use.
The therapeutic landscape is gradually evolving with targeted immunotherapies and peptide-based vaccines designed to promote immune tolerance while reducing adverse effects.
The approval of ODACTRA represented a significant milestone as the first sublingual immunotherapy tablet for HDM-induced allergic rhinitis. However, its boxed warning and limited pediatric safety data continue to present challenges for long-term disease management.
Several late-stage therapies, including PURETHAL Mites, BELTAVAC, and MM09, remain under development, although recent public clinical updates have been limited. None of these candidates has yet reached regulatory submission or commercialization.
Meanwhile, tregalizumab offers a differentiated mechanism by selectively activating regulatory T cells and may become an innovative future treatment for HDMD.
House Dust Mite Disease Competitive Landscape
The emerging HDMD pipeline includes several promising candidates from leading companies, including:
HAL Allergy – PURETHAL Mites
Probelte Pharma – BELTAVAC
Inmunotek – MM09
T-Balance Therapeutics – tregalizumab
PURETHAL Mites is a subcutaneous allergen immunotherapy developed using chemically modified house dust mite extracts (Dermatophagoides pteronyssinus and Dermatophagoides farinae) adsorbed onto aluminum hydroxide. It is currently being evaluated in a Phase III clinical trial.
BELTAVAC is a subcutaneous immunotherapy developed by Probelte Pharma for the treatment of Alternaria mold allergy. It utilizes a chemically modified Dermatophagoides pteronyssinus extract produced through glutaraldehyde polymerization and is also in Phase III clinical development.
The expected launch of these therapies has the potential to reshape the HDMD treatment landscape, offering improved standards of care while creating new opportunities for innovation and market growth.
Discover more about House Dust Mite Disease drugs: House Dust Mite Disease Drugs Market
Recent Developments in the House Dust Mite Disease Market
September 2025: Stallergenes Greer and Nuance Pharma entered an exclusive long-term partnership to develop and commercialize ACTAIR for HDM-induced allergic rhinitis.
July 2025: Stallergenes Greer appointed CEOLIA Pharma as its new promotional partner for ACTAIR in Japan following the conclusion of its licensing agreement with Shionogi.
February 2025: The US FDA approved ALK's ODACTRA for children aged 5–11 years, expanding its indication for HDM-induced allergic rhinitis with or without conjunctivitis.
What is House Dust Mite Disease?
House Dust Mite Disease (HDMD) is a chronic allergic condition caused by hypersensitivity to proteins found in house dust mite feces and body fragments. These microscopic mites commonly inhabit indoor environments such as bedding, carpets, and upholstered furniture.
Exposure to these allergens can trigger an IgE-mediated immune response, resulting in symptoms such as:
Allergic rhinitis
Nasal congestion
Sneezing
Itchy or watery eyes
Chronic cough
Asthma exacerbations
Because exposure is continuous throughout the year, HDMD significantly affects quality of life, sleep, productivity, and long-term respiratory health.
House Dust Mite Disease Epidemiology Segmentation
The House Dust Mite Disease epidemiology section provides insights into the historical and current patient population, along with forecasted trends across the leading markets. HDM allergy is present in up to 90% of Asian atopic patients, significantly higher than the 50% to 70% prevalence reported in Western populations.
The report provides epidemiological analysis for the 2020–2034 study period across the leading markets and includes:
Total Prevalent Population of HDMD
Total Diagnosed Prevalent Population of HDMD
Gender-specific Diagnosed Prevalent Population of HDMD
Allergen-specific Diagnosed Prevalent Population of HDMD
Total Treated Cases of HDMD
House Dust Mite Disease Market Report Metrics
Study Period: 2020–2034
Coverage: 8MM
Market CAGR: 3.5%
Market Size (2024): USD 9.2 Billion
Key Companies: HAL Allergy, Probelte Pharma, Inmunotek, T-Balance Therapeutics, ALK-Abelló, Stallergenes Greer, and others
Key Therapies: House Dust Mite Allergy Vaccine (PURETHAL Mites), BELTAVAC, MM09, Tregalizumab, ODACTRA/ACARIZAX/MITICURE, ACTAIR/ORYLMYTE/AITMYTE, and others
Scope of the House Dust Mite Disease Market Report
The report offers comprehensive coverage of the House Dust Mite Disease market, including:
Assessment of current marketed and emerging therapies
Market dynamics and key forecast assumptions
Future outlook for emerging HDMD therapies
Competitive intelligence, including SWOT analysis and market entry strategies
Unmet medical needs
Key Opinion Leader (KOL) perspectives
Analyst insights
Market access and reimbursement landscape
Download the report to explore the latest research on House Dust Mite Disease: New House Dust Mite Disease Medication
Table of Contents
House Dust Mite Disease Market Key Insights
House Dust Mite Disease Market Report Introduction
Executive Summary of HDMD
Key Events
Epidemiology and Market Forecast Methodology
HDMD Market Overview at a Glance
Disease Background and Overview
House Dust Mite Disease Treatment
Epidemiology and Patient Population
House Dust Mite Disease Patient Journey
Marketed House Dust Mite Disease Drugs
Emerging House Dust Mite Disease Drugs
HDMD Market Analysis (7MM + China)
House Dust Mite Disease Market Unmet Needs
House Dust Mite Disease SWOT Analysis
KOL Views on House Dust Mite Disease
House Dust Mite Disease Market Access and Reimbursement
Bibliography
House Dust Mite Disease Market Report Methodology
Related Reports
Asthma Market
The Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report provides an in-depth understanding of disease epidemiology, historical and forecasted market trends, key growth drivers and barriers, and leading companies, including GlaxoSmithKline, Areteia Therapeutics, Sanofi, Connect Biopharma, Upstream Bio, Teva Pharmaceuticals, Launch Therapeutics, AstraZeneca, Incyte Corporation, and others.
The Severe Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers detailed insights into disease epidemiology, market dynamics, and major companies such as AstraZeneca, GlaxoSmithKline, Sanofi, Novartis, Roche, Teva, Merck, Boehringer Ingelheim, Regeneron, Johnson & Johnson, Pfizer, Bristol Myers Squibb, Eli Lilly, Vertex, Amgen, AbbVie, Genentech, Gilead Sciences, Biogen, CSL, and others.
About DelveInsight
DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences sector. The company supports pharmaceutical and biotechnology organizations by delivering comprehensive, end-to-end market intelligence and consulting solutions that help improve strategic decision-making and business performance.
DelveInsight also provides seamless access to a broad portfolio of healthcare and pharmaceutical market research reports through its subscription-based platform, PharmDelve.
Contact Us
Kanishk
